Forbes October 21, 2020
Jake Becraft

Our biotech industry is working at unprecedented speeds to bring a COVID-19 vaccine to market; rather than unprecedented, these speeds should be the new norm.

“You never let a serious crisis go to waste — it’s an opportunity to do things you think you could not do before.” — Rahm Immanuel

The arrival of COVID-19 has achieved something no other disease before it has — the FDA and drug companies are working closely to accelerate the speed of vaccine and drug development. And while COVID-19 has a much bigger societal impact, the stark reality is that other diseases like cancer or cystic fibrosis are always life-or-death for some part of the population

Our current crisis has shown that when...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Healthcare System, Pharma / Biotech, Public Health / COVID
Biopharma M&A more than doubled in the first quarter compared to the year prior: report
Bruker brokers $392M deal for frayed NanoString
Pharma Pulse 4/18/24: Is it Fair Certain Biotech Investors Get an Early Look? The Health and Healthcare of Millennials & more
23andMine: CEO Wojcicki aims to take genetics company private
AI That Predicts Targeted Cancer Drug Response with Single-Cell Precision

Share This Article